On January 26, 2024, Health Canada issued a notice clarifying that drugs with a “dormant” Drug Identification Number (“DIN”) may not be considered “marketed” for the purposes of the Patented Medicines (Notice of Compliance) Regulations (the “PM(NOC) Regulations”). In our first bulletin on the subject, we reviewed the consequences of that position for innovators relying on Canada’s patent linkage framework to protect their innovative medicines.
Developments since then, including renewed U.S. attention to most‑favored‑nation (“MFN”) drug pricing have heightened the legal and policy concerns associated with that notice. In our view, those concerns merit renewed scrutiny.
A Brief Recap: Dormant DINs and PM(NOC) Protection